Nanologica infectious, drug delivery news
Materials development company Nanologica joined the ORCHID alliance to improve the formulation and solubility of water-insoluble compounds to treat tuberculosis. The company will use its silica-based porous carrier materials to control the release of active compounds through porous particles. The four-year ORCHID alliance, which has €10 million ($13.3 million) in funding from the EU's Seventh Framework Program (FP7), is focused on discovering and developing therapies to treat multiple-drug resistant tuberculosis. The EU is directly contributing €5.4 million ($7.2 million) in funding to the project. Members of ORCHID will research potential therapeutic areas including beta lactams, inhA enoyl-(acyl carrier protein) reductase inhibitors and whole cell anti-tubercular compounds. ...